MAPT and Dravet syndrome: Moreover, we pharmacologically validated the use of CX-4945 in vivo in model organisms by observing the effective rescue of neurological and phenotypic defects in a DS-like Drosophila model, and the significant suppression of Tau phosphorylation in the hippocampus of DS-like mice.